Plant-Based Oral Vaccines Against Zoonotic and Non-Zoonotic Diseases

Naila Shahid  
*University of Pennsylvania*

Henry Daniell  
*University of Pennsylvania*

Follow this and additional works at: [https://repository.upenn.edu/dental_papers](https://repository.upenn.edu/dental_papers)

Part of the Dentistry Commons

**Recommended Citation**
Shahid, N., & Daniell, H. (2016). Plant-Based Oral Vaccines Against Zoonotic and Non-Zoonotic Diseases. *Plant Biotechnology Journal, 14* (11), 2079-2099. [http://dx.doi.org/10.1111/pbi.12604](http://dx.doi.org/10.1111/pbi.12604)

This paper is posted at ScholarlyCommons. [https://repository.upenn.edu/dental_papers/263](https://repository.upenn.edu/dental_papers/263)  
For more information, please contact repository@pobox.upenn.edu.
Plant-Based Oral Vaccines Against Zoonotic and Non-Zoonotic Diseases

Abstract
The shared diseases between animals and humans are known as zoonotic diseases and spread infectious diseases among humans. Zoonotic diseases are not only a major burden to livestock industry but also threaten humans accounting for >60% cases of human illness. About 75% of emerging infectious diseases in humans have been reported to originate from zoonotic pathogens. Because antibiotics are frequently used to protect livestock from bacterial diseases, the development of antibiotic-resistant strains of epidemic and zoonotic pathogens is now a major concern. Live attenuated and killed vaccines are the only option to control these infectious diseases and this approach has been used since 1890. However, major problems with this approach include high cost and injectable vaccines is impractical for >20 billion poultry animals or fish in aquaculture. Plants offer an attractive and affordable platform for vaccines against animal diseases because of their low cost, and they are free of attenuated pathogens and cold chain requirement. Therefore, several plant-based vaccines against human and animals diseases have been developed recently that undergo clinical and regulatory approval. Plant-based vaccines serve as ideal booster vaccines that could eliminate multiple boosters of attenuated bacteria or viruses, but requirement of injectable priming with adjuvant is a current limitation. So, new approaches like oral vaccines are needed to overcome this challenge. In this review, we discuss the progress made in plant-based vaccines against zoonotic or other animal diseases and future challenges in advancing this field.

Keywords
Livestock, molecular farming, oral delivery, animal diseases, veterinary vaccines

Disciplines
Dentistry
Review Article

Plant-based oral vaccines against zoonotic and non-zoonotic diseases

Naila Shahid and Henry Daniell*

Department of Biochemistry, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA, USA

Summary

The shared diseases between animals and humans are known as zoonotic diseases and spread infectious diseases among humans. Zoonotic diseases are not only a major burden to livestock industry but also threaten humans accounting for >60% cases of human illness. About 75% of emerging infectious diseases in humans have been reported to originate from zoonotic pathogens. Because antibiotics are frequently used to protect livestock from bacterial diseases, the development of antibiotic-resistant strains of epidemic and zoonotic pathogens is now a major concern. Live attenuated and killed vaccines are the only option to control these infectious diseases and this approach has been used since 1890. However, major problems with this approach include high cost and injectable vaccines is impractical for >20 billion poultry animals or fish in aquaculture. Plants offer an attractive and affordable platform for vaccines against animal diseases because of their low cost, and they are free of attenuated pathogens and cold chain requirement. Therefore, several plant-based vaccines against human and animals diseases have been developed recently that undergo clinical and regulatory approval. Plant-based vaccines serve as ideal booster vaccines that could eliminate multiple boosters of attenuated bacteria or viruses, but requirement of injectable priming with adjuvant is a current limitation. So, new approaches like oral vaccines are needed to overcome this challenge. In this review, we discuss the progress made in plant-based vaccines against zoonotic or other animal diseases and future challenges in advancing this field.

Introduction

Zoonosis can be defined as transmission of disease between human and animals that happens due to interaction between these two populations. Zoonosis not only interrupts human health but it also affects wild life and livestock industry. Recently, more than 65% of emerging infectious diseases in humans have been reported to originate from zoonotic pathogens (Narrod et al., 2012). Zoonotic diseases can be divided into two categories depending on their mode of transmission. Vector-borne zoonotic infection is transmitted to humans via arthropods carrier and nonvector-borne diseases are transferred by contaminated food or direct contact (Buza et al., 2015). Zoonotic infections in humans started 14 000 years ago when dogs were domesticated for hunting. Other animals like goat, sheep, cattle and pigs were domesticated later for meat or dairy products. This domestication increased not only the interaction between these two populations but also the risk of their cross-contaminating diseases (Thrusfield, 2013).

The plague outbreak that killed a large proportion of the European population was spread through rats and is an example of the profound impact of zoonotic diseases. After smallpox, plague is historically the second most deadly disease in human populations and has caused millions of deaths; the Black Death pandemic in Europe during the 14th–17th centuries caused 200 million deaths and killed one-third of European population (Alvarez and Cardineau, 2010; Perry and Fetherston, 1997). According to an estimate, 31 food-borne pathogens of animal origin in United States cause 9.4 million cases of illness each year. Salmonella spp., norovirus, Campylobacter spp, Toxoplasma gondii, avian influenza virus, swine flu virus, Listeria monocytogenes and norovirus are major pathogens, producing zoonotic infections in humans. Salmonella is a major human health concern in the United States, causing one million cases of illness and 400 deaths annually. Salmonella is the most common pathogen in turkey and poultry and causes multiple human salmonellosis in the United States through contaminated food (Routh et al., 2015). Norovirus is another important zoonotic pathogen in the United States. It is responsible for 50% of food-borne gastroenteritis outbreaks in the United States, leading to 19–21 million cases of illness and 570–800 deaths annually. It is a major cause of viral gastrointestinal outbreaks in cruise ships in the USA and spreads by direct contact. Contaminated food is another important source for the spread of norovirus infection in the United States (Stock et al., 2015). Similarly in Australia 30% illness is caused by food-borne pathogens and in England and Wales 8% illness is due to contaminated food of animal origin by Norovirus. Moreover, people working in production and farm areas are at high risk of acquiring infection from various animals. Farm workers act as channel to spread zoonotic pathogens to the public (Gray and Kayali, 2009). Although zoonotic diseases kill a much larger population in developing countries, accurate documentation or statistics is not available.

Growing populations and increased demand for food have led to increased production of food of animal origin. In most developing countries, almost 66% of the population is protein deficient; the total protein requirement per person is 103 g per day, but protein-deficient individuals consume only 69% of this
amount, most of it in the form of red and white meat. Livestock production has played a major role in meeting this demand. Among livestock, ruminants and poultry are the cheapest and most efficient source of high-quality protein; they can easily compensate for protein deficiencies among the population (Ashraf and Shah, 2014). Livestock production is playing very important role in accomplishing food security, influenced strongly by cultural preferences (Godber and Wall, 2014). According to the United States Department of Agriculture (USDA), current global beef and veal production is almost 59.2 million tons and is expected to increase by 1% in 2016. Pork production is now at 112.0 million tons and is expected to remain stable in 2016, and 89.3 million tons of broiler meat is produced and is expected to rise 2% in 2016. The United States and India are largest producers of beef, whereas Australia is the largest beef supplier. Similarly, the United States, Brazil and China are largest producers of broiler meat (http://www.usda.gov/wps/portal/usda/usdahome). Animals support life on earth by providing high-quality protein through dairy products and meat, but this industry is severely hampered by parasitic and infectious diseases of both endemic and epidemic in nature, negatively impacting global economy (Rich and Perry, 2011). For example, the epidemic outbreak of foot-and-mouth disease in the United Kingdom in 2001 resulted in direct economic loss of $11.9–$18.4 billion including loss of agriculture and food industry (Carpenter et al., 2011). Animal health is an important element in providing safe products to humans. Animal disease management is a major concern for livestock, poultry and fish industries to provide pathogen-free products to the consumer (Kolotilin et al., 2014).

The complex global system and human interaction with pet animal, livestock and poultry has made it essential to consider human and animal health as a common and not two isolated problems. However, development of medicines to control animal diseases is a big challenge in field of veterinary medicine. The major challenges are the cost and volume. Most human vaccines are given as injections and it is impossible to inject large numbers of animals. Lives of farmed animals are very different from their natural lives, as most animals in the United States are reared in factory farms. This favours increased production and maximizes profit margins but also increases the risk of the spread of infectious diseases. Live attenuated and killed vaccines are the only available option to control these infectious diseases. However, the main problem with them is their high cost versus profit, and the use of injectable vaccines is impractical, if not impossible, to control disease in large farms.

Plants offer an attractive and affordable platform for vaccines against animal diseases, especially in industries with low profit margins. So, edible orally delivered, low-cost vaccines are an urgent need in the production of disease-free animals. Topp et al. (2016) recently provided a general overview of efficacy, competitiveness and regulatory approval of plant-made veterinary immunotherapeutics. This manuscript is a highly comprehensive in-depth review of plant-made veterinary vaccines to control zoonotic diseases, which has not been addressed in any previous review. In addition, mechanisms of different vaccine delivery methods and vaccines to control nonzoonotic diseases are also reviewed.

Current strategies to control zoonotic and animal diseases

The first discovery of small pox vaccine by Edward Jenner opened a new world for the prevention of infectious diseases. Since that time, many approaches have been adopted to control humans and animal diseases using essentially the same concept (Joensuu et al., 2008). Behring and Kitasato first introduced the concept of serum therapy when they induced immunity in animals by serum treated with nonlethal toxin dose (Behring et al., 1890). Later on, advancement in proteomics resulted in the use of mouse hybridoma cells from immunized mice to produce specific monoclonal therapeutic antibodies (Köhler and Milstein, 1975) that conferred protection against human diseases. But use of antibody therapy is severely limited by their high production cost. The estimated high production cost for protein drug ($140 billion in 2013) has made them unaffordable in most developing countries, as most people earn less than $2 per day (Kwong and Daniell, 2015). Infectious diseases of animals are a large concern throughout the world, especially in developing countries. It is estimated that 58% human pathogens are zoonotic, that is transmitted from animals, major cause for emerging infectious diseases. Vaccination is the only possible tool to control these infectious diseases especially in animals with short life span (Loza-Rubio and Rojas-Anaya, 2010).

Since 1940, a number of vaccines have been developed using inactivated, attenuated and live viruses. The most common and licensed vaccines against infectious diseases of animals are live attenuated or killed live attenuated pathogens or recombinant proteins. Porcilis-PCV2 and Suvaxyn PCV2 for pigs, Periovac for dogs, AquaVac ERM, AquaVac Furuvac, AquaVac Vibrio for fish are commercialized and licensed vaccines against veterinary diseases (Meeusen et al., 2007). In inactivated virus-based vaccines, the disease-causing virus has been killed by heat, radiation or other methods. The drawback of this type of vaccine is that it causes a weaker immune response than live vaccines and several booster doses are needed to acquire an adequate level of immunity. Live vaccines contain live virus that is weak but still infectious. Live virus-based vaccines are usually prepared in lyophilized form and can be stored for up to 1 year at 4 °C. PreveNile against horses, Vaxithek HVT+BD against poultry, Bovilis IBR Marker against cattle, RECOMBITEK Canine Parvo against dogs, RECOMBITEK Corona MLV against pigs, Enterisol Ileitis against pigs are commercially available live virus vaccines (Meeusen et al., 2007). Live virus vaccines have some disadvantages, as there is always a risk of their regaining virulence. Although these are not well documented in veterinary vaccines because of their short life, they are well documented in human vaccines. Sabin strains used in oral polio vaccine (OPV) revert to virulence by recombination with other enteroviruses or by point mutations (Burns et al., 2014; Runckel et al., 2013). Several decades ago, genetic instability and vaccine-associated paralytic poliomyelitis (VAPP) was reported among recipients of OPV in the United States and their close contacts (Alexander et al., 2004; Schonberger et al., 1976). Outbreaks in the Dominican Republic and Haiti a decade ago (Kew et al., 2002) led to the discovery of circulating vaccine-derived polioviruses (VDPV) (Diop et al., 2015; Lakhani and Bumb, 2014). Therefore, the World Health Organization has recommended complete withdrawal of OPV Type 2 by April 2016 globally (Chan et al., 2016). Such an outbreak of attenuated live vaccines against zoonotic diseases is a major concern. In addition, the mode of delivery of live vaccines via sprays or aerosols pose additional challenges. The aerosol mode of administration can unintentionally inoculate younger or more susceptible animals, which can ultimately cause death (Alexander, 2012).

Advances in biotechnology have resulted in the development of recombinant therapeutics. E. coli was used as first expression
system for the production of recombinant therapeutics. After a number of efforts in the field of recombinant therapeutics and approval of Escherichia coli-expressed recombinant human insulin established the importance of recombinant therapeutics. Recombinant therapeutics production involves the expression and purification of immunogenic antigens instead of the whole virus or pathogens. These recombinant vaccines are useful to control infectious diseases of animals due to reduced risk associated with live and killed viral vaccines. Recombinant therapeutics are expensive to produce but they are found to be effective in humans. There are different systems to produce recombinant therapeutics, including bacteria, insect cells, yeast, mammalian cell culture and transgenic animals. Bacteria and yeast-based production systems are more efficient because of their rapid replication rate. However, recombinant proteins need to be purified to remove host-derived proteins, and this is a major contributing factor to the cost of recombinant therapeutics (Joensuu et al., 2008). The global market of animal vaccine is almost $5507.3 million and it is likely to increase $7197.9 million in 2020. The animal vaccine market is based on poultry diseases, livestock diseases, porcine diseases, aquaculture and equine diseases. The expansion of vaccine market is boosted by many factors, but the main factor is increasing incidence of zoonotic infections in humans, which spreads by direct contact with live and killed viral vaccines. Recombinant therapeutics are expensive to produce but they are found to be effective in humans. There are different systems to produce recombinant therapeutics, including bacteria, insect cells, yeast, mammalian cell culture and transgenic animals. Bacteria and yeast-based production systems are more efficient because of their rapid replication rate. However, recombinant proteins need to be purified to remove host-derived proteins, and this is a major contributing factor to the cost of recombinant therapeutics (Joensuu et al., 2008). The global market of animal vaccine is almost $5507.3 million and it is likely to increase $7197.9 million in 2020. The animal vaccine market is based on poultry diseases, livestock diseases, porcine diseases, aquaculture and equine diseases. The expansion of vaccine market is boosted by many factors, but the main factor is increasing incidence of zoonotic infections in humans, which spreads by direct contact with animals or food-borne pathogens (Kolotilin et al., 2014). Expression of protective antigens in plants is a new vaccination technology that is more economical than any other available system of vaccines production (Joensuu et al., 2008).

Plant-made vaccines against zoonotic and animal diseases

Edible vaccine production for veterinary use has received widespread attention because of health initiatives aimed at decreasing antibiotic use in livestock and other animals to avoid the development of antibiotic-resistant strains, especially of epidemic and zoonotic pathogens. These issues have promoted the development of plant-based vaccines, which can easily fulfil these requirements (Sack et al., 2015). Various vaccines against infectious animal diseases are available in the market and show good results, but they have several disadvantages (Meeusen et al., 2007). The major drawbacks of these vaccines are their complex and expensive production and purification, their requirement for low-temperature storage, safety issues and the need for a skilled person for administration. Subunit vaccines are expensive and difficult to produce and always require low-temperature storage. Apex-HHN against Salmon and West Nile-Innovator DNA against horses are commercially available DNA vaccines, but major drawbacks of DNA vaccines are monotonic responses and require extensive safety protocols (Meeusen et al., 2007). Whole-cell vaccines also have problems associated with administration and low-temperature storage. Another main reason to avoid conventional vaccine for most of viral infection is that their use can affect disease-free status of country by enhancing disease scrutiny. For example, inactivated vaccine for FMD is quite effective but it is still banned in disease-free countries because of its consequence on international trade (Ruiz et al., 2015).

The field of plant genetic engineering started in 1970, when extensive research was carried out to discover ways to utilize plant genetics for reasons other than nutrition. After early studies on expression of a few biopharmaceuticals, antigens against different human and animal diseases were expressed in plants (Liew and Hair-Bejo, 2015). The United States Department of Agriculture (USDA) approved the world’s first plant-based vaccine in 2006. Dow AgroSciences received approval for the first plant-based vaccine against Newcastle disease virus (NDV) from the USDA. Dow Agro Sciences used tobacco suspension cell lines to develop a plant-based vaccine (injectable) against NDV. This vaccine was approved by the USDA in 2006 after showing 90% protection against a challenge with NDV virus. This system can be used to produce a large quantity of antigen in a very short period of a few weeks, but the company did not commercialize the product. Although this is a plant-based vaccine, injectable mode of administration did not offer significant cost advantages. However, the success of the first commercial plant-made vaccine against NDV by Dow Agro Sciences opened the door for the commercialization of plant-made vaccines (Yusibov et al., 2011).

Edible vaccines are actually recombinant vaccines in which selected antigens against a particular pathogen are introduced into a plant. Oral delivery of this plant induces a protective immune response against that particular pathogen in the form of an edible vaccine (Aswathi et al., 2014). Almost 200 proteins have been produced in plants, and their promising results make them new competitors in the field of recombinant proteins. Vaccine production through plants has several advantages over other eukaryotic production systems. They are cost-effective and safe and can be produced in large quantities. With plant-based production systems, a glasshouse or a plot of land can easily replace the expensive use of fermenters (Daniell et al., 2016b, 2009). The estimated cost for plant-based production is much lower as compared to mammalian and E. coli system with basic need of light, water and simple large-scale production method. Vaccine antigen can be delivered easily just in the form of plant material instead of needle-based delivery (Liew and Hair-Bejo, 2015). Plant-based medicines are usually free from the toxins and pathogens that are commonly produced in bacteria and yeast (Kwon et al., 2013). Plant cells expressing vaccine antigens or biopharmaceuticals can be lyophilized and stored at ambient temperature for many years maintaining efficacy of expressed protein drugs (Kwon et al., 2013; Lakshmi et al., 2013; Su et al., 2015; Kwon et al., 2013; Lakshmi et al., 2013; Su et al., 2015). Except for their lower cost, plant-produced proteins and therapeutics are very similar to recombinant proteins that have been produced in eukaryotes (Daniell et al., 2009). Plant-based vaccines or therapeutic proteins can be post-translationally modified. Moreover, glycans are different in plants and animals and this has a strong effect on immunogenicity (Chan and Daniell, 2015; Kwon and Daniell, 2015; Tremblay et al., 2010). They also negate the issue of restored virulence that is associated with live vaccines (Clarke et al., 2013). Plant-based vaccines have the potential to induce a mucosal immune response and a systemic immune response without the pain and risk associated with needles and injections. Another advantage of plant-based vaccines is that they can be given directly to animals after oral priming with adjuvants (Chan and Daniell, 2015). The plant cell wall protects the foreign antigen until it is digested by gut microbes, releasing the antigen and promoting the immune response (Kwon et al., 2013). Animal studies show that these vaccines are protected from degradation by the digestive enzymes of the stomach through bioencapsulation, and they can produce a protective immune response after encountering a pathogen (Figure 1) (Lakshmi et al., 2013). The best plants for edible vaccines are vegetables and fruits like potato, tomato, carrot, maize, banana, lettuce, tobacco, and rice and soya bean. However, it is difficult to control antigen dose in fresh fruits and vegetables. Therefore, plant material should be
freeze-dried to control dose (Chan and Daniell, 2015; Daniell et al., 2016a). When animals eat transgenic seeds, fruit or plants in the form of edible vaccines, mucosal-specific antibodies (Okamura et al., 2014) and serum-specific antibodies (IgG) are produced (Sack et al., 2015). In most animals and birds, the gut-associated lymphoid tissue (GALT) is responsible for inducing an immune response (Aswathi et al., 2014). Antigens from the lumen or intestine are recognized by M cells in the Peyers patches, and M cells activate B lymphocytes with assistance of Th cells. B lymphocytes produce the mucosal immune response and IgA, which kills pathogens by binding to surface proteins. Another method of antigen uptake is mediated by dendritic intestinal cells, which induce a systemic immune response in the form of IgG antibodies. Cytotoxic T lymphocytes (CTL) are activated by Th cells and induce a strong cellular immune response. Thus, edible vaccines have the potential to induce mucosal, systemic and cellular immune responses (Chan and Daniell, 2015; Guan et al., 2013).

Plant expression systems to produce vaccine antigens

Nuclear transformation

Nuclear transformation is the simplest and most extensively used system for the production of genetically modified crops. In this system, a foreign antigen is expressed from the nuclear genome via Agrobacterium tumefaciens or biotic gene gun-mediated transformation (Figure 1a) Agrobacterium tumefaciens is a soil-borne, Gram-negative bacterium that can transform a foreign gene into a host by making a crown gall. Agrobacterium infects plant tissues by sensing the phenolic secretions of wounded plants. These specific signals activate bacterial virulence (Vir) genes that produce Vir proteins. Ti plasmids induce the formation of T-DNA molecules. T-DNA associates with Vir proteins to make a T-DNA complex. A complex network between bacterial Vir proteins and T-DNA ultimately transfers the T-DNA into the nuclear genome of the host plant. The T-DNA principle of gene transfer has made it an important tool in plant genetic engineering to transform foreign genes into plants (Kim and Yang, 2010; Pitzschke, 2013). Foreign genes integrate into the nuclear genome, allowing the continuous production of recombinant protein (Chan and Daniell, 2015; Guan et al., 2013; Tremblay et al., 2010). Another advantage of nuclear transformation is the post-translational modification of recombinant proteins that occurs in this eukaryotic production system. After post-translational modification, depending on signal peptides, proteins can be stored in various organelles or secreted (Tremblay et al., 2010). But there are several disadvantages linked with this system including gene silencing, position effect, low expression level and risk of transgene contamination via pollen or seeds, limiting commercial development of plant-based recombinant vaccines (Fahad et al., 2015). A few transgenic plant-based vaccines have moved forward to clinical trials, but none of them reached beyond phase I clinical trials, mainly due to low expression level that limited their regular approval from FDA. Expressed norovirus capsid protein VP1 in potato tubers against norovirus has been advanced to phase I clinical trials where 20% vaccinated volunteers produced IgG in titre range 1:757. It was prepared by Arizona State University in collaboration with GMP facility (Takeyama et al., 2015). Similarly edible vaccines against enterotoxigenic E. coli in potato and maize have advanced to phase I clinical trials where vaccinated volunteers produced LT-B-specific IgG and IgA. Another, rice-based cholera vaccine that was developed in Japan is now under phase I clinical trials (Takeyama et al., 2015).

Chloroplast transformation

Chloroplast transformation addresses some of the problems of nuclear transformation for commercialization of plant-based recombinant vaccines. In this method, a transgene is introduced into the circular plant chloroplast genome through a particle gun, resulting in site-specific integration by homologous recombination (Figure 1b) (Daniell et al., 2002). In this method, when leaves are bombarded with gold particles coated with chloroplast vectors, transgene cassette integrates into the chloroplast genome. The expression of foreign genes is generally high, as there are 10 000 copies of the chloroplast genome in each leaf cell. As chloroplast genome is maternally inherited, this reduces the risk of transgene escape via pollen. In addition, harvesting of vegetative tissues (leaves) before flowering eliminates escape via pollen or seeds. Therefore, transplastomic plants expressing vaccine antigens and biopharmaceuticals have been grown in the field (Arlen et al., 2007). USDA-APHIS has certified that transplastomic lines do not fit the definition of a regulated article 7 CFR (part 340) because there are no pest components (Kwon and Daniell, 2015). Moreover, expression of multiple gene is possible under a single promoter due to polycistronic expression (De Cosa et al. 2001; Quesada-Vargas et al. 2005). The major regulatory element used in chloroplast transformation is the psbA promoter, 5’ untranslated region (UTR), psbA 3’ untranslated region and the most commonly used spacer region is the trn1 and trnA (Daniell et al., 2016a,b). Such combination facilitates very high levels of transgene expression, even up to 72% of TSP (Chan and Daniell, 2015). Many antigens from viral and bacterial origin has been expressed in chloroplast against different animals diseases including polio, plague, cholera, malaria, canine parvovirus, tuberculosis, anthrax, FMD, rotavirus, classical swine flu virus (Arlen et al., 2008; Gorantala et al., 2014; Lakshmi et al., 2013; Lentz et al., 2010; Ortigosa et al., 2010; Shao et al., 2008; Zhou et al., 2010).

Viral vectors

Another transformation system uses plant viral vectors like cauliflower mosaic virus (CaMV), tobacco mosaic virus, cowpea mosaic virus, bamboo mosaic virus or alfalfa mosaic virus (Figure 1c). In this method, the plant virus is genetically engineered to be under the control of the coat protein subgenomic mRNA promoter. The coat protein is highly expressed in an infected host, making it the best promoter to express foreign genes. Copies of the infectious nucleic acid deliver the target gene to the plant cell. They produce virus-like particles that deliver the peptide epitope. This process of infecting most plant tissues takes almost 3 weeks (Gleba et al., 2007). The plant virus system has resulted in the production of vaccines against rabies in which modified alfalfa mosaic virus CP glycoprotein G and the nucleoprotein were expressed by the viral vector system and conferred protection in mice after viral challenge. Plant-based rabies vaccines is in phase I clinical trials; five of nine volunteers produced neutralizing antibodies against rabies virus (Rybicki, 2014; Takeyama et al., 2015). Plant viruses are independently transcribed and translated to produce abundant proteins in a short time (Guan et al., 2013).

In plant virus and agrobacterium based transformation, Agrobacterium promotes the entry of multiple copies of recombinant viral vectors into plant cells. The target gene is delivered
Figure 1 Mechanism for production of plant-based oral vaccines against animal diseases. (a) Nuclear expression of foreign antigens via Agrobacterium tumefaciens-mediated transformation followed by selection and propagation in the glasshouse. (b) In chloroplast transformation, a transgene is introduced into the plant chloroplast genome using a particle gun, resulting in site-specific integration by homologous recombination. (c) Transient expression system based on engineered virus and Agrobacterium tumefaciens to express foreign antigens in plant cells. (d) Cell suspension culture derived from transformed calli expressing vaccine antigens. (e) Harvested leaves are lyophilized to produce dry powder that can be stored for many years without losing efficacy of expressed vaccine antigens. Orally immunization of animals with feed pellets or seeds from transgenic plants for immunization against target pathogens.
through *Agrobacterium* by one of two methods: injecting the stomata of leaves or vacuum infiltration. In vacuum infiltration, upper parts of a plant are flooded with a culture of *Agrobacterium* and a vacuum is applied to remove air from intracellular spaces. Upon release, the vacuum delivers the target gene to plant cells via *Agrobacterium* (Ling et al., 2010). Transcripts of the recombinant viral genome enter the nucleus and cytoplasm of plant cells. As a result, plants start producing large quantities of the target protein within a few days (Yusibov and Rabindran, 2008). This transient expression system has produced target proteins against *Bacillus anthracis*, *Yersinia* pestis and influenza virus (Chichester et al., 2007; Shoji et al., 2008). Transient expression system also resulted in the production of different veterinary vaccines against bluetongue virus, Crimean-Congo haemorrhagic fever virus, Ebola virus, Rift Valley fever virus with promising results (Rybicki, 2014).

Transient expression system with both viral vector- and agrobacterium-mediated delivery of virus replicon is the most preferred method to achieve high level expression of foreign genes. Transient expression system has produced a number of medically important antigens against different diseases. The magnICON technology is also a modification in transient expression to enhance gene expression. Ma et al. (2012) used modified magnICON tobacco mosaic virus-based transient expression system to produce plant-made PyMSP119 against malaria. The highest expression level reached up to 23% of TSP (Fahad et al., 2015; Ma et al., 2012). Larsen and Curtis (2012) used replicating PVX vectors and a nonreplicating CPMV-HT vector and achieved the highest expression of heterologous protein in tobacco hairy roots almost 27.6% of TSP (Larsen and Curtis, 2012).

**Cell suspension cultures**

Cell suspensions are individual cells or cell aggregates that are derivatives of callus tissues; separated callus cells propagate to produce a stable cell suspension (Figure 1d). Transgenic explants or a single callus cell can produce recombinant antigens via transformation with *Agrobacterium* and can then be easily scaled up in a fermenter. In 2006, the USDA approved the world’s first edible vaccine against poultry diseases, which was prepared in tobacco cell suspension (Yusibov and Rabindran, 2008). In 2012, FDA approved the first biopharmaceutical for protein made in carrot cells—glucocerebrosidase to treat Gaucher’s disease. This protein was developed by an Israeli company Protalix Biotherapeutics, and FDA-approved product is now marketed by Pfizer (Wolfson, 2013).

**Strategies to enhance expression of vaccine antigens**

In early work on edible vaccines, the expression level of expressed antigen was not high, for example rotavirus VP6 protein in potatoes produced low expression 0.02% of TSP (Matsumura et al., 2002) and infectious bronchitis S1 protein in potatoes resulted in low expression 0.07%–0.22% of TSP (Zhou et al., 2003). Therefore, low expression level was a major limiting factor in the field of plant vaccines. Different strategies have been adopted to increase expression of transformed genes. In particular, extensive effort has been made to improve expression of transgenes to make edible vaccines more immunogenic. One of the most common approaches is the use of suitable promoters. The CaMV 35S promoter is constitutive and is used in dicotyledonous plants. It is the promoter of choice for expressing foreign antigens in all parts of most dicotyledonous plants. The ubiquitin promoter is commonly used in monocotyledonous plants, and the actin promoter is used for rice. However, several studies have shown that foreign gene expression may be enhanced by tissue- or organ-specific promoters. For example, tomatoes transformed via *Agrobacterium* with the cholera toxin-B subunit (CTB) gene regulated by the CaMV 35S promoter expressed CTB at 0.2%-0.4% of total soluble protein (TSP). By contrast, tomato plants transformed with the same CTB gene but under the control of the E8 tomatto fruit-specific promoter expressed CTB at almost 0.8% of TSP (Guan et al., 2013). Low expression level may be due to prokaryotic nature of CTB but expressed via the eukaryotic nuclear genome. So, codon optimization is another approach to maximize the expression of foreign genes. In this approach, codons of the foreign gene are replaced by preferred codons of the host plant. Mason et al. (1998) studied the expression of the native and codon-optimized heat-labile enterotoxin-B subunit (LTB) gene from *E. coli*. Expression of the codon-optimized LTB gene was quite high almost 0.9–12.8 µg/g of tuber and 0.17–1.85 µg/mg of total protein as compared with the native bacterial gene (Mason et al., 1998). The use of signal peptides also enhances expression of foreign genes. In plant cells, the endoplasmic reticulum stabilizes foreign proteins and promotes their maturation/processing. It has been suggested that an endoplasmic signal peptide at the C-terminus of recombinant proteins could enhance expression (Guan et al., 2013).

Chloroplast expression system has helped address challenges in low expression level and a number of vaccines antigens against cholera, tetanus, anthrax, plague, polio or canine parvovirus achieving up to 13.17% and 10.11% of TSP in dual cholera and malaria vaccine expressing CTB-fused apical membrane antigen 1 (AMA1) and merozoite surface protein 1 (MSP1) (Davoodi-Semiromi et al., 2010) and >70% of TSP for CTB–proinsulin (Ruhlman et al., 2010). These are a few illustrative examples, but readers referred recent reviews where a more comprehensive list of vaccine antigens or biopharmaceuticals expressed in chloroplasts are provided (Daniell et al., 2016a,b; Davoodi-Semiromi et al., 2010; Jin and Daniell, 2015). When eukaryotic human or viral genes are expressed in prokaryotic chloroplasts, expression levels could be very low. However, codon optimization by elimination of rare codons and use of codon usage hierarchy from 130 sequenced chloroplast genomes has resulted in >50-fold high level expression (Chan et al., 2016; Daniell et al., 2016a).

**Vaccine delivery systems**

**Parenteral delivery**

Syringe and needle-based injections is the most common method for the administration of vaccines in which vaccines can be delivered through intradermal, intramuscular and subcutaneous route. Vaccines are delivered in the dermis layer in intradermal route, muscular layer below dermis in intramuscular route and fatty tissue between dermis and muscular layer in case of subcutaneous mode of delivery. Immune response in parenteral delivery depends on adopted method for delivery of vaccine antigen. The administration of inactive vaccines in most of animals is very laborious because of intramuscular or subcutaneous injections. Inactive vaccines can produce very low systematic immunity. In humans, needle-based delivery is associated with infections and inadequate maintenance of cold chain during transportation (Kwon et al., 2013).
Mucosal delivery

Our digestive tract is covered by mucosal layer, richly supplied with blood vessels that directly enter into jejunal vein. Mucosal delivery system directly transports vaccine antigens to immune cells in the mucosal layer and to the blood circulation system. Oral and nasal routes are most common routes for delivery and much more convenient for both humans and animals as compared to injectable mode of delivery (Kwon et al., 2013). Amani et al. (2011) reported that subcutaneous and orally immunized mice with plant-derived EspA, intimin and Tir proteins (EltS) produced significant anti-Elt IgG and faecal IgA, but no IgA was observed in case of parenteral delivery (Amani et al., 2011). In another study, orally immunized mice with CTB (cholera toxin-B subunit)-fused malarial antigens (AMA1) and (MSP1) produced antigen-specific antibodies and showed protection against malarial parasite and cholera toxin challenge (Davoodi-Semiromi et al., 2010), conferring both mucosal immunity and systemic immunity. In a recent study, injected polio vaccine did not generate any IgA, but oral polio vaccine made in plant cells generated both IgA and IgG1 and neutralized all three polio serotypes (Chan et al., 2016).

Intranasal delivery is also effective as it is richly supplied by dendritic cells (DCs). Most of live vaccines in animals are delivered as sprays or aerosols. The major drawback of live virus vaccines is that although they are given to animals of a specific age, the aerosol mode of administration can unintentionally inoculate younger or more susceptible animals, which can ultimately cause death (Alexander, 2012; Kwon et al., 2013).

Oral delivery

Promising results of orally delivered plant-based vaccines offer a new opportunity to address current challenges in their delivery because gut is the largest surface area for absorption in the body. Moreover, gut immune system is very important to control infections because it acts as the first line of defence against infecting pathogens (Azizi et al., 2010). Plant cell wall protects vaccine antigens from degradation by acidic environment in digestive system before it reaches the gut where commensal microbes digest cell wall and release vaccine antigens in the gut lumen (Kwon et al., 2013). Antigen uptake across the gut epithelium is facilitated by tags fused to antigens for specific delivery to immune cells (Xiao et al., 2016) CTB, LTB or DCs peptides act as carriers for antigen delivery to immune cells. CTB assembles as pentameric structures and binds to GM1 receptors in intestinal epithelial cells. Oral delivery of plant-based vaccine against different animal diseases has showed promising results. Orally immunized mice with FIV antigen against plaque produced high titres of IgG1, IgA and 88% mice were protected after lethal aerosol challenge of Yersinia pestis (Arlen et al., 2008). In another study, orally immunized mice with plant cells produced CTB-specific intestinal IgA and serum IgG and showed 100% protection against cholera toxin challenge (Davoodi-Semiromi et al., 2010). Similarly when mice and pigs were orally immunized with E2 glycoprotein against swine flu virus, they produced the E2-specific systematic, mucosal and cellular immune responses (Jung et al., 2014). Similarly, orally immunized mice with HS of (HPAI) A against bird flu elicited high level of HA-specific systematic IgG and mucosal IgA, strong Th1 responses together with IgG2b production and 72% mice were protected after viral challenge (Lee et al., 2015). Another proof for oral delivery of plant-based vaccines was observed in orally immunized pigs against porcine reproductive and respiratory syndrome, pigs fed with transgenic plant cells produced antigen-specific IgA and IgG and neutralizing antibodies (Chia et al., 2010). Chan et al. (2016) produced oral booster vaccines against poliovirus as WHO approves complete replacement of oral polio vaccine (OPV) with one dose of inactivated poliovirus vaccines. Oral boosting of highly expressed VP1 gene in plant chloroplasts using plant-based adjuvants, after single priming with IPV, produced high-titre IgG1 and IgA against VP1 protein, but IPV alone did not produce any IgA. Two doses of IPV or single IPV priming followed by oral boosters resulted in the production of high levels of neutralizing antibodies against all three poliovirus Sabin serotypes. However, single dose of IPV produced low levels of IgG1, neutralizing antibodies but no IgA (Chan et al., 2016).

Oral vaccines against major zoonotic diseases

Viral diseases

Rabies is the most common zoonotic infection that circulates among dogs and wild bats. It is a major cause of economic loss in livestock industry and animals get infected by biting of vampire bats. A number of rabies cases in humans in Latin America have been reported due to bat biting. Rabies is a major public health concern in developing countries as it caused 55 000 deaths annually according to WHO report and millions of death in animals (Loza-Rubio et al., 2012). Rabies infection spreads through a virus that belongs to the family Rhabdoviridae. Currently available vaccines are satisfactory but requirement for refrigeration at 4 °C and high cost are serious limitations in developing countries. Plant-based vaccines offer potential solutions to these problems (Loza-Rubio et al., 2012). Transiently expressed nucleoprotein of rabies virus produced high level expression and was immunogenic in mice and conferred protection against rabies viral challenge (Arango et al., 2008). Singh et al. (2015) fused ricin toxin-B chain (rgp-rtxB) with this glycoprotein in tomato hairy roots, which produced immune response after intramuscular immunization. The high affinity of CTB to GM1 receptors confirmed its anticholera toxin and antibabes antibodies (Roy et al., 2010). Plant-based rabies vaccines, expressed transiently in spinach, is in phase I clinical trials; five of nine volunteers produced neutralizing antibodies against rabies virus (Takeyama et al., 2015).

The swine flu virus belongs to the family Flaviviridae, which causes contagious swine flu disease in pigs and is a major burden in the livestock industry. Influenza is also a major challenge in humans as it has been estimated that millions of people each year are vaccinated against flu. Influenza virus infects farm animals and transmits to humans either by direct contact or through contaminated food. Many cases were reported where pig farmers showed symptoms similar to swine influenza after interaction with infected pigs. In 2009, outbreak of swine influenza caused 17 000 deaths around the world (WHO Situation updates—Pandemic (H1N1) 2009 http://www.who.int/csr/disease/swineflu/updates/en). Many vaccination strategies are in practice to control swine flu fever including live attenuated vaccines but there are some drawbacks of live vaccine including high cost of production, virus inversion and low-temperature storage requirement. Oral and plant-based vaccines offer alternative solutions (Jung et al., 2014). E2 structural protein expressed in tobacco chloroplasts conferred protective immune response in mice upon oral delivery (Shao et al., 2008). Jung et al. (2014) also produced transgenic rice calli expressing E2 structural protein and observed protective
immune response in orally immunized mice; pigs generated E2-specific systemic, mucosal and cellular immune responses.

Avian influenza is highly infectious and contagious disease that can cause 100% mortality in livestock. As this disease is usually spread in large farms, massive vaccinations are needed to control disease in birds and animals. Plant-based vaccines offer the best solution to control this disease in large animal farms (Firsov et al., 2015). Expressed HA in endoplasmic reticulum from avian influenza HPA1 resulted in high level expression; immunogenicity of transgenic Arabidopsis was confirmed from orally immunized mice with high-level HA-specific systemic IgG and mucosal IgA, strong Th1 responses together with IgG2b production and 72% of immunized mice were protected after viral challenge (Lee et al., 2015). In 2009, in response to pandemic swine flu, USDA sponsored US$100 million by funding four companies: Fraunhofer USA Center in Delaware, Kentucky Bioprocessing in Owensboro, Medicago USA in North Carolina, Texas A&M University system and G-Con from Texas, to produce 100 million doses of influenza vaccines. Medicago Inc. developed more than 100 million doses of virus-like particles (VLP)-based influenza vaccines against H5 strain that is now undergoing phase II clinical trials and H5N1 transient expression-based vaccine has completed its phase I and II clinical trials (Rybicki, 2014).

**Bacterial diseases**

Anthrax is the most common emerging zoonotic infection that is spread by the bacterium *Bacillus anthracis*. Anthrax was used as a biological weapon in 2001 and killed five people in the United States. Anthrax outbreaks have been continuously recorded in Asia, Africa and South America. Anthrax is an animal disease, but humans get infected during hunting, through contaminated food or direct contact with animals. Current vaccines against human and animal anthrax are injectable protective antigen obtained from culture filtrate on *Bacillus anthracis*. There are several limitations to this vaccine, including requirement of several boosters (up to eight) and withdrawal of certain batches due to toxin contamination in the culture filtrate. Koya et al. (2005) produced transplastomic tobacco by expressing the anthrax protective antigen (PA) and observed protective immune response in immunized mice producing high-titre IgG antibodies against anthrax (1:320,000) and conferred 100% protection against challenge with lethal dose of *Bacillus anthracis*. Protective immune response was confirmed by oral feeding with transgenic plants and challenge with lethal dose of *Bacillus anthracis*. Orally immunized mice produced IgA, IgG1, IgG2a titres and showed 60%–80% protection after challenge (Gorantala et al., 2011).

*Yersinia pestis*, a bacterial and zoonotic pathogen, is the causative agent of infectious plague in humans. Plague infection can be bubonic (infection in lymph nodes), septicemic (infection in blood vessels) or pneumonic (infection in lungs). Plague causes severe infection in humans with 90% mortality if remained untreated. Animals particularly rodents are the main reservoir of *Yersinia pestis*. Humans get infected by rats through fleas. Few recent plague outbreaks have been reported, including those in Asia. Currently available vaccines use live attenuated or killed *Y. pestis* with certain risks; so there is no approved plague vaccines in the United States, even though CDC lists this among biological weapons (category A) (Sinclair et al., 2008). Arlen et al. (2008) expressed high levels of F1-V in tobacco chloroplasts and orally fed mice were highly immunogenic and showed 88% protection after *Y. pestis* lethal challenge. F1-V expressed in lettuce chloroplasts produced much lower level of antigens but showed immunogenicity (Arlen et al., 2008; Rosales-Mendoza et al., 2010).

Tuberculosis (TB) is zoonotic and infectious disease of bacterial origin in both animals and humans. In 2010, TB affected 8.8 million people and resulted in 1.5 million deaths. TB has a high mortality rate as every minute it causes the death of four of twenty infected people. In developed countries, TB has been mostly eliminated but it is still a problem in most of the developing countries. *M. tuberculosis* is causative agent of TB in humans, while bovine acquires TB infection with *M. bovis*. Both species are closely related. *M. bovis* is risky in humans as 10% TB infection in humans is zoonotic due to *M. bovis* (Müller et al., 2013). BCG is only available vaccine for tuberculosis but this has several limitations; drug-resistant TB is yet another emerging challenge. Plant-based vaccine could offer potential solutions. Transgenic modified carrot with *Mycobacterium tuberculosis* genes of *cp10*, *esat6* and *dipF* produced very low levels of antigen (0.035% TSP), and orally immunized mice with transgenic carrot produced both cell-mediated and humoral immune responses (Permyakova et al., 2015). Chloroplast transformation of CFB-fused ESAt6 and Mtb72F in tobacco and lettuce leaves produced much higher level of expression (up to 7.5% TSP) and lyophilized plant cells could be stored at ambient temperature for several months, thereby eliminating the cold chain and this could facilitate development of an affordable vaccine (Lakshmi et al., 2013).

Listeriosis is an infectious zoonotic disease in humans and animals that is caused by the bacterium *Listeria monocytogenes*. This disease is transmitted to humans through contaminated or uncooked food. Infection can be severe in newborn, pregnant women and individuals with weak immune system. Severe complications lead to encephalitis. Listeriosis is a neglected zoonotic pathogen and plant-based vaccines could offer the best solution for Listeriosis. An attempt was made to produce plant-based vaccine against Listeriosis in which orally immunized mice with transgenic potato showed very promising results by significantly reducing the bacterial burden in spleen and liver after challenge with *Listeria monocytogenes* (Ohya et al., 2005).

Pasteurellosis is also a common infection found in humans and animals that is caused by the bacterium *Pasteurella*. It is responsible for a huge loss in cattle and pig industry, and infection is transmitted to humans by animals bite and contaminated food. An attempt to produce low-cost edible vaccines against Pasteurellosis resulted in a significant immune response in rabbits fed with plant-based GS60 (Lee et al., 2008).

**Parasitic diseases**

*Toxoplasma gondii* causes congenital, neurological and ocular toxoplasmosis in birds, humans and mammals. It is also a zoonotic parasitic pathogen that is transmitted to humans through contaminated food or direct exposure to contaminated soil; infection can be severe among pregnant women and immunocompromised individuals (Chan and Daniell, 2015; Jones et al., 2007). GRA4 antigen from *T. gondii* was expressed in chloroplasts; orally immunized mice with transgenic leaves produced cellular and mucosal immune responses and reduced cyst burden by 60% in mice brain after challenge with *T. gondii* (Yáccono et al., 2012). In another study, fusion of heat-shock protein of LiHsp83 to SAG1 enhanced expression of SAG1 in tobacco chloroplasts and reduced cyst load in mice upon oral delivery (Albarracín et al., 2015).

Malaria is another devastating diseases spread by *Plasmodium falciparum*, causing 500 million illness cases, 1 million deaths
| Diseases | Expressed antigen | Expression system | Expression host | Expression level | Immune response | References |
|----------|------------------|------------------|-----------------|-----------------|-----------------|------------|
| Anthrax (Bacillus anthracis) | PA (protective antigen) | Transplastomic | Tobacco | 4.5–18.5 of TSP | Immunized mice produced high-titre IgG antibodies against anthrax almost 1 : 320 000; 100% protection was observed in immunized mice after challenge with lethal dose of Bacillus anthracis. | Koya et al. (2005) |
| | [PA(DIV)] | Transplastomic | Tobacco | 5.3% of TSP | Immunized mice produced PA-specific IgA and IgG. Higher titre of IgG antibodies was observed at 5th bleed up to 2.4 × 105 100% protection was observed in immunized mice after challenge with lethal dose of Bacillus anthracis. | Gorantala et al. (2011) |
| | PA (protective antigen) | Transplastomic | Tobacco | 2.5%–4% of TSP | Immunized mice produced PA-specific IgA and IgG. Higher titre of IgG antibodies was observed at 5th bleed up to 3.5 × 104 and 7.7 × 104. 100% protection was observed in immunized mice after challenge with lethal dose of Bacillus anthracis. | Gorantala et al. (2014) |
| Rabies Virus | PA (protective antigen) | Transplastomic | Lettuce | 7% of TSP | Not done | Rasouli et al. (2014) |
| | G protein of rabies virus | Transgenic | Carrot | 0.4%–1.2% of TSP | Immunized mice produce antibodies against rabies and 66% immunized mice showed protection against virus challenge | Rojas-Anaya et al. (2009) |
| | G protein fused with CTB | Transient | Tobacco | 0.4% of TSP | Not done | Roy et al. (2010) |
| | G protein of rabies virus | Transgenic | Maize | 25 μg/g of fresh seed tissue | Immunized sheep with transgenic maize produced antibodies against rabies virus and 50%–83% protection was observed in immunized sheep after virus challenge | Loza-Rubio et al. (2012) |
| | Rabies virus G protein | Transgenic | Tomato hairy roots | 0.9%–1.1% of TSP | Immunized mice with RGP-RTP produced specific immune response against RGP-RTP in the form of IgG1, IgG2, TH2 lymphocyte | Singh et al. (2015) |
| Diseases                          | Expressed antigen | Expression system | Expression host | Expression level | Immune response                                                                 | References                  |
|----------------------------------|-------------------|-------------------|----------------|-----------------|---------------------------------------------------------------------------------|-----------------------------|
| Plague                           | F1-V              | Transplastomic    | Tobacco        | 14.8% of TSP    | Oralilly immunized mice produced high-titre IgG1, IgG2a, IgA and 88% mice were protected after lethal dose of Y. pestis challenge | Arlen et al. (2008)         |
|                                  | F1-V              | Transgenic        | Lettuce        | 0.08% of TSP    | Immunized mice produced higher IgG1 and IgG2; no virus challenge assay was performed | Rosales-Mendoza et al. (2010) |
|                                  | F1-V              | Transgenic        | Carrot         | 0.3% of TSP     | Immunized mice produced higher IgG1 and IgG2; no virus challenge assay was performed | Rosales-Mendoza et al. (2011) |
| Swine Flu Classic                | E2 glycoprotein   | Transgenic        | Lettuce/alfalfa| 10 µg/g of lyophilized leaves for alfalfa and 160 µg/g of dry leaf for lettuce | Serum and faecal pellet from immunized mice confirmed the presence of IgA and IgG | Legacki et al. (2005)       |
|                                  | E2 glycoprotein   | Transplastomic    | Tobacco        | 1%–2% of TSP    | Oralilly immunized mice did not produce any specific response as compared to subcutaneous immunization which produced CSFV-specific serum IgG | Shao et al. (2008)          |
|                                  | E2 glycoprotein   | Cell suspension culture | Rice    | 5.1 µg/mg of transgenic callus | Oralilly immunized mice and pig had the E2-specific systematic, mucosal immune responses and cellular immune response was also observed in the form of different cytokines | Jung et al. (2014)          |
| Bird flu Avian                   | NA gene of H1N1   | Transgenic        | Lettuce        | 0.018%–0.045% of TSP | Oralilly immunized mice produced significant anti-NA antibodies at third booster; no virus challenge assay was performed | Liu et al. (2012)           |
| Influenza Virus (AIV)            | M2e Peptide of H5N1 | Transgenic        | Duckweed plant | 0.12%–1.96% of TSP | Not done | Oralilly immunized mice elicited high level of HA-specific systematic IgG and mucosal IgA, strong Th1 responses together with IgG2b production was observed, and 72% protection was observed to immunized mice after virus challenge | Firsov et al. (2015)         |
|                                  | H5 of (HPAI) A    | Transgenic        | Arabidopsis    | 700 µg/g (dry weight) or 140 µg/g (fresh leaf) by ER targeting | Not done | Oralilly immunized mice elicited high level of HA-specific systematic IgG and mucosal IgA, strong Th1 responses together with IgG2b production was observed, and 72% protection was observed to immunized mice after virus challenge | Lee et al. (2015)           |
|                                  | NP of H3N2        | Transgenic        | Maize          | 8.0–35 µg/g of corn seed | Production of IgA, IgG, IgG2, TH1, TH2 from immunized mice confirmed systematic, mucosal and cell-mediated immune responses | Nahampun et al. (2015)      |
| Diseases          | Expressed antigen | Expression system | Expression host | Expression level | Immune response                                                                 | References          |
|-------------------|-------------------|-------------------|----------------|-----------------|--------------------------------------------------------------------------------|---------------------|
| Rotavirus         | VP6 gene          | Transient         | Chenopodium leaves | 0.25% of TSP or 1.54 µg/g of fresh leaves | Orally immunized mice produced anti-VP6-specific serum IgG and significant increase in titre of saliva IgA was observed. 60% mice protection was observed after virus challenge | Zhou et al. (2010)  |
|                   | C486 BRV VP8 protein | Transplastomic | Tobacco         | 600 µg/g of fresh tissue | High titre of IgG antibodies specific to VP8 was observed from sera of immunized mice, and 80%–100% protection was observed in newly born mice from immunized female after rotavirus challenge. | Lentz et al. (2011) |
|                   | MucoRice-ARP1 (heavy chain antibody fragment) | Transgenic       | Rice            | 11.9% of TSP | Administration of MucoRice-ARP reduced the symptoms of disease, and neutralization assay performed in MA104 cells showed complete protection against rotavirus infection. | Tokuhara (2013)     |
| Tuberculosis (Mycobacterium tuberculosis) | Ag85B, MPT83, MPT64, ESAT6 | Transgenic       | Potato          | Not reported | Immunized mice produced high-titre IgG and IgA antibodies against antigens, and stimulated CD4+ and CD8+ led to increased production of Th cells and cytokines | Zhang et al. (2012) |
|                   | ESAT6 and CFP10  | Transgenic       | Carrot          | 0.002%–0.056% of TSP | Immunized mice elicited both cell-mediated and humoral immune responses | Uvarova et al. (2013) |
|                   | CFP10, ESAT6, dIFN | Transgenic       | Carrot          | 0.035% of TSP | Immunized mice confirmed both cellular and humoral immune responses | Permyakova et al. (2015) |
| Brucellosis       | U-Omp19           | Transient         | Tobacco         | Not reported | Immunized mice produced specific response in the form of CD4+ T cells, IL17 and protected against a mucosal challenge with Brucella abortus | Pasquevich et al. (2011) |
| Toxoplasmosis     | Gra4              | Transplastomic    | Tobacco         | 0.2% of TSP | Orally immunized mice produced cellular and mucosal immune response | Yácono et al. (2012) |
|                   | SAG1              | Transient         | Tobacco         | 0.1–1.3 µg/g of Fresh weight | Immunized mice with transgenic SAG1 leaf extracts were protected against cyst challenge, and production | Lagúa-Becher et al. (2010) |
| Diseases                        | Expressed antigen | Expression system | Expression host | Expression level | Immune response                                                                 | References          |
|--------------------------------|-------------------|-------------------|-----------------|-----------------|----------------------------------------------------------------------------------|---------------------|
| Gastroenteritis Transmissible Gastroenteritis Virus (TGEV) | S protein of TGEV | Transgenic        | Corn             | 0.1%–0.8% of TSP | Immunized pig produced IgA, IgG and neutralizing antibodies                        | Lamphear et al. (2004) |
|                                | SIP               | Transient         | Tobacco         | 2% of TSP       | Neutralizing antibodies were confirmed in vitro on mammalian cell and in vivo, immunized pigs produced 60%–70% neutralizing antibodies | Monger et al. (2006) |
| Crimean-Congo Haemorrhagic Fever Virus (CCHFV) | G1 & G2           | Transgenic        | Tobacco         | 0.45% of TSP in hairy roots | Orally immunized mice produce G1/G2 specific IgG with titer range (1 : 65 536) and faecal IgA with titer range (1 : 512) and IgG confirmed mucosal and humoral immune responses | Ghiasi et al. (2011) |
| Japanese Encephalitis Virus Tremblay et al. (2010) | E protein         | Transgenic        | Rice            | 1.1–1.9 μg/mg of TSP | Production of JEV-specific IgA and IgG confirmed mucosal and humoral immune responses | Wang et al. (2009)  |
| West Nile Virus                | VLPs from Norwalk virus and (mAbs) from West Nile and Ebola viruses | Transient         | Lettuce         | 0.23–0.27 mg/g of fresh leave weight | Immune studies not performed but focussed on reduction in neutralizing assay confirmed neutralizing antibodies against WNV | Lai et al. (2012)   |
| Pasteurellosis                 | GS60              | Transgenic/Transient | Alfalfa/Tobacco | 0.02% of TSP for transgenic plants | Immunized rabbit with transgenic alfalfa produced antibodies against GS60 | Lee et al. (2008)  |
| (Listeriosis) Listeria monocyto genes | IFN-α             | Transgenic        | Potato           | Not reported    | Orally immunized mice with transgenic IFN-α showed its ability to reduce bacterial burden as compared to nontransgenic plants | Ohya et al. (2005)  |
annually. Currently, there is no licensed vaccine and promising results of plant-based vaccines against malaria are under development. Davoodi-Semiromi et al. (2010) fused (CTB) *Vibrio cholerae* with malarial vaccine antigens apical membrane antigen-1 (AMA1) and merozoite surface protein-1 (MSP1). They observed high level expression (up to 14% TSP) of CTB-AMA1 and CTB-MSP1 in lettuce and tobacco chloroplasts. Orally immunized mice with CTB (cholera toxin-B subunit)-fused malarial antigens (AMA1) and (MSP1) produced antigen-specific antibodies and showed protection against malarial parasite and cholera toxin challenge (Davoodi-Semiromi et al., 2010). Jones et al. (2013) expressed engineered VLPs fused with Pfs25 and alfalfa mosaic virus coat protein (Pfs25-CP VLP) in tobacco plants using a tobacco mosaic virus-based ‘launch’ vector system. Immunization of mice with one or two doses of purified Pfs25-CP VLPs induced antibodies with transmission blocking activity that was persistent for 6 months postimmunization. Similarly, in another study, Pfs25 gene fused with lichenase (LicKM) carrier was transiently expressed in tobacco plants; immunized mice and rabbits with transgenic tobacco produced transmission blocking antibodies that have been persisted up to 6 months (Jones et al., 2015). Table 1 summarizes the plant-based oral vaccines against zoonotic diseases.

### Oral vaccines against nonzoonotic animal diseases

Health of animals is very important for security of humans as 71% of emerging diseases in humans are due to zoonotic pathogens. A number of successful efforts have been made to produce plant-made veterinary vaccines against nonzoonotic pathogens that are quite severe in animals, leading to major losses in livestock industry. Foot-and-mouth disease is common in bovine, horse, sheep, pig and goat that cause high fever, weight loss and erosions in feet and mouth. This is a major challenge in livestock economy by reducing milk and meat production (Ruiz et al., 2015). Rao et al. (2012) produced a bivalent vaccine against foot-and-mouth diseases expressing VP1 structural protein from two serotypes A and O. Oral feeding of pig with transgenic plants produced specific humoral immune response. Sera from immunized pigs when challenged with FMDV neutralized the virus with no cytopathic effect on BHK-21 cells (Rao et al., 2012). In another approach, VP1 protein was expressed in tobacco chloroplasts (Lentz et al., 2010). Several attempts have been made to express BVDV in tobacco (Nelson et al., 2012), alfalfa (Aguirreburualde et al., 2013) and Panax ginseng (Gao et al., 2015) and their immune studies in different animal models showed promising results.

A number of plant-based vaccines have also been made against different animal diseases. Pig oedema causes heavy economic loss and mortality. It mostly happens in piglets after weaning and its neurological disorder cause sudden death of piglets. Currently, no vaccine is available to protect pigs from oedema diseases. Expressed antigens in plants against pig oedema disease offer potential solutions. Orally Immunized mice and pigs with tobacco seeds expressing Vi2e-B and FedA conferred protective immune response against O138 *E. coli*, and immunized pigs showed protection against O138 *E. coli* infection (Rossi et al., 2014). Antigen expressed in tobacco (Chia et al., 2010) and banana (Chan et al., 2013) against porcine reproductive and respiratory syndrome (PRRSV) showed promising results.

Poultry is a major industry but unfortunately its growth is severely threatened by a number of pathogens of both zoonotic and nonzoonotic origin. Currently worldwide poultry production

| Disease          | Expressed antigen | Expression system | Expression host | Expression level | Immune response | References                  |
|------------------|-------------------|-------------------|----------------|----------------|----------------|-----------------------------|
| Newcastle Disease Virus (NDV) | HN gene | Transgenic | Tobacco | 0.069% of TSP | anti-HN serum IgG, no virus challenge study | Hahn et al. (2007) |
|                  | F and HN | Transgenic | Potato | 0.3–0.6 mg/mg of TSP | NDV-specific IgA and IgG | Gomez et al. (2008) |
|                  | HN gene | Transgenic | Centella asiatica | Not reported | NDV-specific antibodies | Song Lai et al. (2012) |
|                  | HN ectodomain | Transgenic | Tobacco | Not reported | NDV-specific antibodies | Lai et al. (2013) |
|                  | F and HN epitope | Transient | Tobacco | Not reported | Not reported | Shahriari et al. (2015) |

© 2016 The Authors. *Plant Biotechnology Journal* published by Society for Experimental Biology and The Association of Applied Biologists and John Wiley & Sons Ltd., 14, 2079–2099
Table 2 Vaccine antigens against Animals Diseases expressed in edible plants or tobacco

| Diseases | Expressed antigen | Expression system | Expression host | Expression level | Immune response                                                                 | References |
|----------|-------------------|-------------------|-----------------|-----------------|--------------------------------------------------------------------------------|------------|
| Foot-and-Mouth Disease virus (FMDV) | VP1 protein | Transplastomic | Tobacco | 51% of TSP | Orally immunized Balb/c mice produced anti-VP1 FMDV-specific antibodies | Lentz et al. (2010) |
|         | Two serotypes of VP1, O- and Asia 1-type Polypeptide P1 gene | Transgenic | Maize | Not done | Not reported | Zhang et al. (2011) |
|         | Two serotypes of VP1, O-A | Transgenic | Rice | 0.6–1.3 μg/mg of TSP | FMDV-specific IgG and IGA were detected, and 20%–40% mice showed clearance of virus after virus challenge | Wang et al. (2012) |
|         | VPI capsid protein | Transient | Tobacco | Not reported | Not reported | Habbibi-Pirkoohi et al. (2014) |
| Bovine Viral Diarrhoea Virus (BVDV) | E2 glycoprotein | Transient | Tobacco | 600 μg/g of fresh leave | Sera of Immunized guinea pig were tested by indirect ELISA, which produced high titres of anti-BVDV-specific antibodies. Neutralization assay from guinea pig sera in MDBK cells showed the production of neutralizing antibodies after BVDV challenge | Nelson et al. (2012) |
|         | E2 glycoprotein | Transgenic | Alfalfa | 1 μg/g of fresh leaf weight | Immunized guinea pig produced high titre of neutralizing antibodies almost more than 2.4 against BVDV, incubated MDBK cells with sera from immunized guinea also confirmed viral antigen after virus neutralization assay | Aguirrebustuialde et al. (2013) |
|         | E0 glycoprotein | Transgenic | Astragalus | Not reported | Immunized deer produced humoral and cell-mediated immune responses against BVDV | Gao et al. (2014) |
|         | Erns glycoprotein | Transgenic | Panax ginseng | Not reported | Immunized deer produced humoral and cell-mediated immune responses against BVDV | Gao et al. (2015) |
| Peste des Petits Ruminant Virus (PPRV) | HN protein | Transgenic | Peanut plant | Not reported | Immunized sheep with transgenic leaves produced HN-specific antibodies against PPRV and serum from immunized sheep reacted and showed proliferation in PPRV-infected VERO cells as compared to control | Khandelwal et al. (2011) |
| Diseases | Expressed antigen | Expression system | Expression host | Expression level | Immune response | References |
|----------|-------------------|-------------------|----------------|-----------------|----------------|------------|
| Pig oedema | Stx2EB | Transgenic | Lettuce | 80 mg per 100 g fresh weight | Not done | Matsui et al. (2011) |
| | Vt2e-B and F18 | Transgenic | Tobacco | 0.3% of TSP of 0.6 mg seeds | Immunized mice with tobacco seeds confirmed the increased numbers of mucosal IgA-producing cells by immunohistochemistry of small and large intestines | Rossi et al. (2013) |
| | Vt2e-B and FedA subunit of F18 | Transgenic | Tobacco | Not done | Orally immunized mice with FedA and VT2eB produced protective immune response against E. coli strain. The immunized pigs appeared preventing the symptoms of disease after challenge with O138 E. coli strain | Rossi et al. (2014) |
| E. coli-mediated Diarrhoea in Pigs (ETEC) | faeG gene | Transplastomic | Tobacco | 0.15% of TSP | Orally immunized mice produced FaeG-specific antibodies. Moreover, sera from immunized mice confirmed neutralizing effect from ETEC in rabbits by ideal loop assay | Shen et al. (2010) |
| Porcine Epidemic Diarrhoea Virus (PEDV) | CTB-fused COE | Transgenic | Lettuce | 0.0065% of TSP | Not done | Huy et al. (2011) |
| | M cell-fused COE | Transgenic | Rice | 0.083% of TSP | Isolated lymphocyte from spleen and Peyer's patches of immunized mice confirmed three- to four-fold higher level of COE-specific IgA and IgG as compared to wild type | Huy et al. (2012) |
| Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) | ORF5 | Transgenic | Tobacco | 0.011% of TSP | Orally immunized pigs confirmed significant amount of anti-PRRSV IgG from sera and IgA from saliva. Serum from immunized pigs also confirmed neutralizing antibodies at titre of 1 : 8 | Chia et al. (2010) |
| | ORF5 | Transgenic | Banana | 0.021%–0.037% of TSP | Immunized pigs by oral feeding of transgenic banana leaves produced strong serum and saliva anti-PRRSV response. Virus challenge to immunized pigs decreased viral load in tissues by producing neutralizing antibodies | Chan et al. (2013) |
| Diseases                                  | Expressed antigen                  | Expression system | Expression host | Expression level | Immune response                                                                 | References                          |
|------------------------------------------|------------------------------------|-------------------|----------------|-----------------|--------------------------------------------------------------------------------|-------------------------------------|
| Expressed Antigens in Plants against Poultry Diseases |                                    |                   |                |                 |                                                                                  |                                     |
| Coccidiosis                              | EtMIC2 from Eimeria tenella        | Transient         | Tobacco        | Not reported    | Immunized birds produced high-titre serum IgG with an average 940 on 21st day and 1340 on 28th day. Partial protection in birds was observed after challenge with virulent E. tenella oocysts | Sathish et al. (2011)                |
|                                         | EtMIC1 and EtMIC2 from Eimeria tenella | Transient         | Tobacco        | 25 mg/kg of fresh biomass | Immune birds with bivalent formulation produced better systemic immune response and better protection against challenge as compared to monovalent formulation | Sathish et al. (2012)                |
| Infectious Bursal Disease Virus (IBDV)   | VP2 antigen from IBDV              | Transient         | Tobacco        | Not reported    | Immunized chicken produced high-titre IBDV-specific IgG and were protected from IBDV challenge | Chen et al. (2012)                   |
|                                         | VP2                                | Transient         | Tobacco        | 1% of TSP       | Intramuscularly immunized chicken with transgenic tobacco elicited specific humoral response and neutralizing antibodies | Gómez et al. (2013)                  |
| Expressed Antigens in Plants against Dog diseases |                                    |                   |                |                 |                                                                                  |                                     |
| Canine Parvovirus (CPV)                  | CTB-fused 2L21 and GFP-fused 2L21 | Transplastomic    | Tobacco        | 31% of TSP for CTB-2L21 and 22.6 of TSP for GFP-2L21 | Immunized Balb/c mice with leaf extract from CTB-fused 2L21 and GFP-fused 2L21 produced anti-2L21 antibodies with titre range from 200 to 25 000, and anti-VP2 response against viral VP2 protein confirmed its protective immune response against CPV | Molina et al. (2004)                |
|                                         | CTB-fused 2L21                     | Transplastomic    | Tobacco        | 31% of TSP       | Immunized mice with CTB-2L21 produced high-titre IgG and IgA with ability to recognize viral protein VP2 | Molina et al. (2005)                |
|                                         | VP2 gene 2L21-TD (Tetramerization domain p53) | Transgenic        | Tobacco        | 6% of TSP       | Not done                                                                 | Xiong et al. (2008)                 |
|                                         |                                    | Transplastomic    | Tobacco        | Not done        | Immunized mice with 2L21-TD produced high-titre antibodies and its ability to recognize viral protein VP2 confirmed the antigenicity of 2L21-TD | Ortigosa et al. (2010)              |
| Expressed Antigens in Plants against Rabbit Diseases |                                    |                   |                |                 |                                                                                  |                                     |
| Rabbit Haemorrhagic Disease Virus (RHDV) | VP60                               | Transient         | Arabidopsis    | 0.3%–0.8% of TSP | Immunized mice with transgenic crude extracts produced specific antibodies against VP60 with titre range between 1 : 10 000 and 1 : 32 000 | Gil et al. (2006)                   |
Table 2

| Diseases | Expressed antigen | Expression system | Expression host | Expression level | Immune response | Reference(s) |
|----------|-------------------|-------------------|-----------------|-----------------|----------------|--------------|
| VP60 Transgenic | Multiple plants | 0.01%-0.7% of TSP | Immunized rabbits produced and protected from RHDV challenge. | Kohl et al. (2006) | Anti-VP60-specific antibodies and protected from RHDV challenge. | et al. (2009) |
| L1 capsid protein | Tobacco | 1.0 mg/kg for transient and up to 0.4 mg/kg for transient | protected from virus challenge, but in vitro assay did not show any neutralization efficiency | Companjen et al. (2009) | Oral feeding of mice by plant-based fusion protein produced specific antibodies against viral VP2 protein. | et al. (2006) |
| Papillomavirus (CRPV) | Transgenic/Tobacco | Not reported | Oral feeding of mice by plant-based fusion protein produced specific antibodies against viral VP2 protein. | Companjen et al. (2009) | Expression level and energy cost. Plants after 5 weeks of seeding in growth time and energy cost. | et al. (2006) |
| Canine parvovirus, HA from Influenza virus | Transgenic E. coli (Aquaculture) | LTB fused to GFP, VP from Canine parvovirus, HA from Influenza virus | Edible vaccine against Aquaculture E. coli (Aquaculture) | Not reported | Polared livers | et al. (2006) |

Plant-based oral veterinary vaccines is almost 86 million tons and it is likely to increase to 94 million tons in the near future. Currently emerging diseases in field of poultry also lead to development of plant-based vaccines against different poultry diseases. NDV, infectious bursal diseases, avian influenza, coccidiosis are most severe diseases in poultry. Infectious bursal disease is the most important disease in young chickens that causes high mortality. Currently available vaccines are live and killed virus, which are protective but associated with some disadvantages. VP2 is most selected antigen in plant-based vaccine against infectious bursal disease virus (IBDV) due to its immunogenic and virus neutralizing ability. Edible vaccines against IBDV have been developed in tobacco (Chen et al., 2012; Gómez et al., 2013) and rice (Wu et al., 2007). Immunized chickens not only produced antibodies against IBDV but also showed protection against IBDV challenge.

Canine parovirus causes infection in dogs and particularly in puppies. The importance of dog cannot be denied among domesticated animals. Currently live and killed virus-based vaccines offer the only solution to treat dogs with CPV infection. Live vaccines are always associated with pathogen of low virulence that can be hazardous for dogs with weak immune systems. Many efforts in the field of plant-based vaccines have been made to find alternate solution to treat or prevent CPV in dogs. Immunization of mice with CTB-2L21 and GFP-2L21 peptide from (CPV) VP2 protein (Molina et al., 2004) and 2L21-TD (Ortigosa et al., 2010) expressed in chloroplasts generated high titres of IgA, IgG1 antibodies against viral VP2 protein. In another approach, antigens expressed in Arabidopsis against rabbit haemorrhagic disease virus (RHDV) (Gil et al., 2006) and in tobacco against cottontail rabbit papillomavirus (CRPV) (Kohl et al., 2006) showed immunogenicity and promising results. Table 2 summarizes the plant-based vaccines against non-zoonotic infections.

Current facilities for the production of plant-based vaccines

The recent advancement and successful approaches to develop plant-derived vaccines have attracted attention for creating large commercial facilities to produce large quantities of vaccine antigens under good manufacturing practice (cGMP) standards. The first set-up for commercial- and large-scale production of plant-derived vaccines was developed in 1999 and was based on transient expression systems. After that, extensive progress was made in the field of plant vaccines: high-level expression was achieved and the concepts of plant virus vectors and the vacuum infiltration process were introduced. In 2007, the Defense Advanced Research Project Agency (DARPA) funded a project for the development of CGMP manufacturing units for large-scale, rapid production of plant-derived vaccines. After realizing that low-cost, plant-derived vaccines are a better tool to control many infectious diseases in humans, DARPA financed projects at Kentucky BioProcessing (Owensboro, KY), Medicago (Durham, NC) and Caliber Bio Therapeutics (Bryan, TX) for the development of cGMP facilities for plant-made vaccines. Caliber Biotherapeutics is currently the largest manufacturing facility and can produce 3500 kg of plant material at one time under LED illumination system, automatic hydroponic facility and high-throughput infiltration system. LED illumination system has reduced growth time and energy cost. Plants after 5 weeks of seeding in automated hydroponic system under constant LED light are moved to the infiltration area, which is 18.3-metre-long vessel with ability to hold 7000 L infiltrate. After infiltration, plants are placed on postinfiltration growth racks for 6-10 days, then transported to
harvest area and finally driven to downstream area for final purification. As a world’s largest plant-based manufacturing facility, it produced more than 100 million doses of H1N1 influenza subunit vaccines for phase I clinical trials. This investment in cGMP manufacturing units is a major advance in the field of plant-based vaccines and will permit the production of large quantities of vaccines at the time of an outbreak (Holtz et al., 2015).

Conclusions

Major efforts have been made during last decade to use plants to express foreign antigens against various animal and human diseases. The success of the first commercial plant-made vaccine against NDV by Dow Agro Sciences and FDA approval of biopharmaceutical to treat Gaucher’s disease produced in carrot cells offer hope for rapid commercialization of plant-made vaccines. Moreover, successful human trials of plant-based vaccines against norovirus, influenza, rotavirus, rabies, *E. coli* and HBV infections also contribute to this growing industry. Plant-made vaccines possess all the desirable attributes of vaccines including long-term storage and stability at room temperature. But the main challenge in plant-based vaccines is the need for oral priming with adjuvants. So, new techniques/concepts are needed to overcome this challenge.

Acknowledgements

Research reported from the Daniell laboratory was supported by NIH grants R01 HL107904, R01 HL109442, R01 EY024564 and Bill and Melinda Gates Foundation grant OPP1031406 to Henry Daniell. Naila Shahaid training in the Daniell laboratory at the University of Pennsylvania was supported by the Higher Education Commission, Pakistan (PINF # 112–26729–28m1–396).

Conflict of interest statement

Henry Daniell, as a pioneer in the field of chloroplast genetic engineering, has several patents in this field but has no financial conflict of interest to declare.

References

Aguirreburualde, M.S.P., Gómez, M.C., Ostachuk, A., Wolman, F., Albasnesi, G., Pecora, A., Odeon, A. et al. (2013) Efficacy of a BVDV subunit vaccine produced in alfalfa transgenic plants. *Vet. Immunol. Immunopathol.* **151**, 315–324.

Albarracín, R.M., Becher, M.L., Farran, I., Sander, V.A., Corigliano, M.G., Yácono, M.L., Farían, S. et al. (2015) The fusion of Toxoplasma gondii gondii SAG1 vaccine candidate to Leishmania infantum heat shock protein 83-kDa improves expression levels in tobacco chloroplasts. *Biotechnol. J.* **10**, 748–759.

Alexander, D.I. (2012) *Newcastle Disease*. Kluwer Academic Publisher, Volume 8, 10.1007/978-1-4613-1759-3. Springer Science & Business Media.

Alexander, L.N., Seward, J.F., Santibanez, T.A., Pallansch, M.A., Kew, O.M., Prevots, D.R., Strebel, P.M. et al. (2004) Vaccine policy changes and epidemiology of poliomyelitis in the United States. *JAMA* **292**, 1696–1701.

Alvarez, M.L. and Cardineau, G.A. (2010) Prevention of bubonic and pneumonic plague using plant-derived vaccines. *Biotechnol. Adv.* **28**, 184–196.

Amanzi, J., Mousavi, S.L., Rafati, S. and Salmanian, A.H. (2011) Immunogenicity of a plant-derived edible chimeric EsPik, Intimin and Tir of *Escherichia coli* O157: H7 in mice. *Plant Sci.* **180**, 620–627.

Arango, J.P., Rubio, E.L., Anaya, E.R., Flores, T.O., de la Vera, L.G. Lim, M.A.G. (2008) Expression of the rabies virus nucleoprotein in plants at high-levels and evaluation of immune responses in mice. *Plant Cell Rep.* **27**, 677–685.
antigens confer dual immunity against cholera and malaria by oral or injectable delivery. Plant Biotechnol. J. 8, 223–242.

De Cosa, B., Moor, W., Lee, S.-B., Miller, M. and Daniell, H. (2001) Overexpression of the Bt cry2Aa2 operon in chloroplasts leads to formation of insecticidal crystals. Nat. Biotechnol. 19, 71–74.

Diop, O.M., Burns, C.C., Sutter, R.W., Wisslak, S.G. and Kew, O.M. (2015) Update on vaccine-derived poliaviruses—worldwide, January 2014–March 2015. MMWR Morb. Mortal. Wkly Rep. 64, 640–646.

Fahad, S., Khan, F.A., Pandupusipatan, N.S., Ahmed, M.M., Liao, Y.C., Waheed, M.T., Sameeullah, M. et al. (2015) Recent developments in therapeutic protein expression technologies in plants. Biotechnol. Lett. 37, 265–279.

Fristov, A., Tarasenko, I., Mitsouchkina, T., Irmaliova, N., Shalako, L., Vainstein, A. and Dolgov, S. (2015) High-yield expression of M2e peptide of avian influenza virus H5N1 in transgenic duckweed plants. Mol. Biotechnol. 57, 653–661.

Gao, Y., Zhao, X., Zang, F., Liu, Q., Wei, G. and Zhang, L. (2014) Generation of the bovine viral diarrhea virus E0 Protein in transgenic asparagus and its immunogenicity in Sika Deer. Evidence-Based Complement. Alternat. Med. 2014, 7pp. doi:10.1155/2014/372503.

Gao, Y., Zhao, X., Sun, C., Zang, P., Yang, H., Li, R. and Zhang, L. (2015) A transgenic ginseng vaccine for bovine viral diarrhea. Virol. J. 12, 73.

Ghiasi, S.M., Salmanian, A., Chinkar, S. and Zakeri, S. (2011) Mice orally immunized with a transgenic plant expressing the glycoprotein of Crimean-Congo hemorrhagic fever virus. Clin. Vaccine Immunol. 18, 2031–2037.

Gil, F., Titarenko, E., Terrada, E., Arcalis, E. and Escribano, J.M. (2006) Successful oral prime-immunization with VP60 from rabbit haemorrhagic disease virus produced in transgenic plants using different fusion strategies. Plant Biotechnol. J. 4, 135–143.

Gleba, Y., Klimyuk, V. and Marillonnet, S. (2007) Viral vectors for the expression of proteins in plants. Curr. Opin. Biotechnol. 18, 134–141.

Godber, O.F. and Wall, R. (2014) Livestock and food security: vulnerability to population growth and climate change. Glob. Change Biol. 20, 3092–3102.

Gómez, E., Zoth, S.C., Carrillo, E., Roux, M.E. and Berinstein, A. (2008) Mucosal immunity induced by orally administered transgenic plants. Immunobiology, 213, 671–675.

Gómez, E., Lucero, M.S., Zoth, S.C., Carballoa, J.M., Gravissaco, M.J. and Berinstein, A. (2013) Transient expression of VP2 in Nicotiana benthamiana and its use as a plant-based vaccine against infectious bursal disease virus. Vaccine, 31, 2623–2627.

Gorantala, J., Grover, S., Rahi, A., Chaudhary, P., Rajwanshi, R., Sarin, N.B. and Daniell, H. (2001) Recent developments in therapeutic protein expression technologies in plants. Biotechnol. Lett. 23, 1180–1189.

Hahn, B.-S., Jeon, I.-S., Jung, Y.-J., Kim, J.-B., Park, J.-S., Ha, S.-H., Kim, K.-H. et al. (2007) Expression of hemagglutinin-neuraminidase protein of Newcastle disease virus in transgenic tobacco. Plant Biotechnol. Rep. 1, 85–92.

Holtz, R.B., Beroukhist, J.D., Kommineni, V.J., Muniruggi, R.K., White, E.L., Wilkerson, D.C. et al. (2015) Commercial-scale biopharmaceuticals manufacturing facility for plant-made pharmaceuticals. Plant Biotechnol. J. 13, 1180–1190.

Huy, N.-X., Kim, S.-H., Yang, M.-S. and Kim, T.-G. (2012) Immunogenicity of a neutralizing epitope from porcine epidemic diarrhea virus: M cell targeting ligand fusion protein expressed in transgenic rice calli. Plant Cell Rep. 31, 1933–1942.

Jin, S. and Daniell, H. (2015) The engineered chloroplast genome just got smarter. Trends Plant Sci. 20, 622–640.

Joensuu, J., Niklander-Teeri, V. and Brandle, J. (2008) Transgenic plants for animal health: plant-made vaccine antigens for animal infectious disease control. Phytochem. Rev. 7, 533–577.

Jones, J.L., Kuszon-Moran, D., Sanders-Lewis, K. and Wilson, M. (2007) Toxoplasma gondii infection in the United States, 1999–2004, decline from the prior decade. Am. J. Trop. Med. Hygiene. 77, 405–410.

Jones, R.M., Chichester, J.A., Mente, V., Jaje, J., Totttey, S., Manceva, S., Casta, L.J., Gibbs, S.K., Muschky, K. and Shamlou, M. (2013) A plant-produced PfS25 VLP malaria vaccine candidate induces persistent transmission blocking antibodies against Plasmodium falciparum in immunized mice. PLoS ONE, 8, doi:10.1371/journal.pone.0079538.

Jones, R.M., Chichester, J.A., Manceva, S., Gibbs, S.K., Muschky, K., Shamlou, M., Nokirke, J. et al. (2015) A novel plant-produced PfS25 fusion subunit vaccine induces long-lasting transmission blocking antibody responses. Hum. Vaccin. Immunother. 11, 124–132.

Jung, M., Shin, Y.J., Kim, J., Cha, S.-B., Lee, W.-J., Shin, M.-K., Shin, S.W. et al. (2014) Induction of immune responses in mice and pigs by oral administration of classical swine fever virus E2 protein expressed in rice cell. Arch. Virol. 159, 3219–3230.

Kew, O., Morris-Glasgow, V., Landaverde, M., Burns, C., Shaw, J., Garib, Z.A., André, J. et al. (2002) Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science, 296, 356–359.

Khandelwal, A., Renukaradhya, G.J., Rajasekhar, M., Sita, G.L. and Shailla, M.S. (2011) Immune responses to hemagglutinin-neuraminidase protein of pestes des petits ruminants virus expressed in transgenic peanut plants in sheep. Vet. Immunol. Immunopathol. 140, 291–296.

Kim, T.-G. and Yang, M.-S. (2010) Current trends in edible vaccine development using transgenic plants. Biotechnol. Bioprocess Eng. 15, 61–65.

Kohl, T., Hitzeroth, I., Stewart, D., Varsani, A., Govan, V., Christensen, N., Williamson, A.-L. et al. (2006) Plant-produced cottontail rabbit papillomavirus L1 protein protects against tumor challenge: a proof-of-concept study. Clin. Vaccine Immunol. 13, 845–853.

Köhler, G. and Milstein, C. (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 269, 495–497.

Kolotulin, I., Topp, E., Cox, D., Devriendt, B., Conrad, U., Joensuu, J., Stöger, E. et al. (2014) Plant-based solutions for veterinary immunotherapeutics and prophylactics. Vet. Res. 45, 375.

Koya, V., Moayeri, M., Leppla, S.H. and Daniell, H. (2005) Plant-based vaccine: mice immunized with chloroplast-derived anthrax protective antigen survive anthrax lethal toxin challenge. Infect. Immun. 73, 8266–8274.

Kwon, K.C. and Daniell, H. (2015) Low-cost oral delivery of protein drugs bioencapsulated in plant cells. Plant Biotechnol. J. 13, 1017–1022.

Kwon, K.-C., Verma, D., Singh, N.D., Herzog, R. and Daniell, H. (2013) Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells. Adv. Drug Deliv. Rev. 65, 782–799.

Lagula-Becher, M., Martin, V., Kraemer, M., Corigliano, M., Yascono, M.L., Goldman, A. and Clemente, M. (2010) Effect of codon optimization and subcellular targeting on Toxoplasma gondii antigen SAG1 expression in tobacco leaves to use in subcutaneous and oral immunization in mice. BMC Biotechnol. 10, 52.

Lai, H., He, J., Engle, M., Diamond, M.S. and Chen, Q. (2012) Robust production of virus-like particles and monoclonal antibodies with geminivirus replicon vectors in lettuce. Plant Biotechnol. J. 10, 95–104.

Lai, K.S., Yusoff, K. and Mahmood, M. (2013) Functional ectodomain of the hemagglutinin-neuraminidase protein is expressed in transgenic tobacco cells as a candidate vaccine against Newcastle disease virus. Plant Cell, Tissue Organ Cult. (PCTOC) 112, 117–121.

Lakhani, D. and Bumb, S.S. (2014) Polio eradication in India: a journey from a dream to reality. Int. J. Sci. Study, 2, 1–1c.

Lakshmi, P.S., Verma, D., Yang, X., Loid, B. and Daniell, H. (2013) Low cost tuberculosis vaccine antigens in capsules: expression in chloroplasts, bio-encapsulation, stability and functional evaluation in vitro. PLoS ONE, 8, e54708.
Lamphear, B.J., Ilka, J.M., Kesi, L., Welter, M., Howard, J.A. and Streetfild, S.J. (2004) A corn-based delivery system for animal vaccines: an oral transmissible gastroenteritis virus vaccine boosts lactogenic immunity in swine. Vaccine, 22, 2420–2424.
Larsen, J.S. and Curtis, W.R. (2012) RNA viral vectors for improved Agrobacterium-mediated transient expression of heterologous proteins in Nicotiana benthamiana cell suspensions and hairy roots. BMC Biotechnol. 12, 21.
Lee, R.W., Cornelise, M., Ziauddin, A., Stack, P.J., Hodgins, D.C., Stroemer, J.N., Shewen, P.E. et al. (2008) Expression of a modified Mannheimia haemolytica GS60 outer membrane lipoprotein in transgenic alfalfa for the development of an edible vaccine against bovine pneumonic pasteurellosis. J. Biotechnol. 135, 224–231.
Lee, G., Na, Y.J., Yang, B.G., Choi, J.P., Seo, Y.B., Hong, C.P., Yun, C.H. et al. (2015) Oral immunization of haemagglutinin H5 expressed in plant endoplasmic reticulum with adjuvant saponin protects mice against highly pathogenic avian influenza A virus infection. Plant Biotechnol. J. 13, 62–70.
Legocki, A.B., Miedzinska, K., Czapliński, M., Plucieniak, A. and Wędrychowicz, H. (2005) Immunoprotective properties of transgenic plants expressing E2 glycoprotein from CSFV and cysteine protease from Fasciola hepatica. Vaccine, 23, 1844–1846.
Lentz, E.M., Segretin, M.E., Morgenfeld, M.M., Wirth, S.A., Santos, M.J.D., Liew, P.S. and Hair-Bejo, M. (2015) Farming of plant-based veterinary vaccines for veterinary purposes. Expert rev. Vaccines 14, 859–868.
Larsen, J.S. and Curtis, W.R. (2012) RNA viral vectors for improved Agrobacterium-mediated transient expression of heterologous proteins in Nicotiana benthamiana cell suspensions and hairy roots. BMC Biotechnol. 12, 21.
Lee, G., Na, Y.J., Yang, B.G., Choi, J.P., Seo, Y.B., Hong, C.P., Yun, C.H. et al. (2015) Oral immunization of haemagglutinin H5 expressed in plant endoplasmic reticulum with adjuvant saponin protects mice against highly pathogenic avian influenza A virus infection. Plant Biotechnol. J. 13, 62–70.
Legocki, A.B., Miedzinska, K., Czapliński, M., Plucieniak, A. and Wędrychowicz, H. (2005) Immunoprotective properties of transgenic plants expressing E2 glycoprotein from CSFV and cysteine protease from Fasciola hepatica. Vaccine, 23, 1844–1846.
Lentz, E.M., Segretin, M.E., Morgenfeld, M.M., Wirth, S.A., Santos, M.J.D., Liew, P.S. and Hair-Bejo, M. (2015) Farming of plant-based veterinary vaccines for veterinary purposes. Expert rev. Vaccines 14, 859–868.
Larsen, J.S. and Curtis, W.R. (2012) RNA viral vectors for improved Agrobacterium-mediated transient expression of heterologous proteins in Nicotiana benthamiana cell suspensions and hairy roots. BMC Biotechnol. 12, 21.
Lee, G., Na, Y.J., Yang, B.G., Choi, J.P., Seo, Y.B., Hong, C.P., Yun, C.H. et al. (2015) Oral immunization of haemagglutinin H5 expressed in plant endoplasmic reticulum with adjuvant saponin protects mice against highly pathogenic avian influenza A virus infection. Plant Biotechnol. J. 13, 62–70.
Legocki, A.B., Miedzinska, K., Czapliński, M., Plucieniak, A. and Wędrychowicz, H. (2005) Immunoprotective properties of transgenic plants expressing E2 glycoprotein from CSFV and cysteine protease from Fasciola hepatica. Vaccine, 23, 1844–1846.
Lentz, E.M., Segretin, M.E., Morgenfeld, M.M., Wirth, S.A., Santos, M.J.D., Liew, P.S. and Hair-Bejo, M. (2015) Farming of plant-based veterinary vaccines for veterinary purposes. Expert rev. Vaccines 14, 859–868.
Larsen, J.S. and Curtis, W.R. (2012) RNA viral vectors for improved Agrobacterium-mediated transient expression of heterologous proteins in Nicotiana benthamiana cell suspensions and hairy roots. BMC Biotechnol. 12, 21.
Lee, G., Na, Y.J., Yang, B.G., Choi, J.P., Seo, Y.B., Hong, C.P., Yun, C.H. et al. (2015) Oral immunization of haemagglutinin H5 expressed in plant endoplasmic reticulum with adjuvant saponin protects mice against highly pathogenic avian influenza A virus infection. Plant Biotechnol. J. 13, 62–70.
Legocki, A.B., Miedzinska, K., Czapliński, M., Plucieniak, A. and Wędrychowicz, H. (2005) Immunoprotective properties of transgenic plants expressing E2 glycoprotein from CSFV and cysteine protease from Fasciola hepatica. Vaccine, 23, 1844–1846.
Lentz, E.M., Segretin, M.E., Morgenfeld, M.M., Wirth, S.A., Santos, M.J.D., Liew, P.S. and Hair-Bejo, M. (2015) Farming of plant-based veterinary vaccines for veterinary purposes. Expert rev. Vaccines 14, 859–868.
Larsen, J.S. and Curtis, W.R. (2012) RNA viral vectors for improved Agrobacterium-mediated transient expression of heterologous proteins in Nicotiana benthamiana cell suspensions and hairy roots. BMC Biotechnol. 12, 21.
Lee, G., Na, Y.J., Yang, B.G., Choi, J.P., Seo, Y.B., Hong, C.P., Yun, C.H. et al. (2015) Oral immunization of haemagglutinin H5 expressed in plant endoplasmic reticulum with adjuvant saponin protects mice against highly pathogenic avian influenza A virus infection. Plant Biotechnol. J. 13, 62–70.
Legocki, A.B., Miedzinska, K., Czapliński, M., Plucieniak, A. and Wędrychowicz, H. (2005) Immunoprotective properties of transgenic plants expressing E2 glycoprotein from CSFV and cysteine protease from Fasciola hepatica. Vaccine, 23, 1844–1846.
Lentz, E.M., Segretin, M.E., Morgenfeld, M.M., Wirth, S.A., Santos, M.J.D., Liew, P.S. and Hair-Bejo, M. (2015) Farming of plant-based veterinary vaccines for veterinary purposes. Expert rev. Vaccines 14, 859–868.
Larsen, J.S. and Curtis, W.R. (2012) RNA viral vectors for improved Agrobacterium-mediated transient expression of heterologous proteins in Nicotiana benthamiana cell suspensions and hairy roots. BMC Biotechnol. 12, 21.
Lee, G., Na, Y.J., Yang, B.G., Choi, J.P., Seo, Y.B., Hong, C.P., Yun, C.H. et al. (2015) Oral immunization of haemagglutinin H5 expressed in plant endoplasmic reticulum with adjuvant saponin protects mice against highly pathogenic avian influenza A virus infection. Plant Biotechnol. J. 13, 62–70.
Rossi, L., Di Giancamillo, A., Reggi, S., Domeneghini, C., Baldi, A., Sala, V., Dell’Orta, V. et al. (2013) Expression of verrucovirus Escherichia coli antigens in tobacco seeds and evaluation of gut immunity after oral administration in mouse model. J. Vet. Sci. 14, 263–270.

Rossi, L., Dell’Orto, V., Vagni, S., Sala, V., Reggi, S. and Baldi, A. (2014) Protective effect of oral administration of transgenic tobacco seeds against verrucovirus Escherichia coli strain in piglets. Vet. Res. Commun. 38, 39–49.

Routh, J., Pringle, J., Mohr, M., Bidel, S., Arends, K., Adams-Cameron, M., Hancock, W. et al. (2015) Nationwide outbreak of multidrug-resistant Salmonella Heidelberg infections associated with ground turkey: United States, 2011. Epidemiol. Infect. 143, 3227–3234.

Roy, S., Tyagi, A., Tiwari, S., Singh, A., Sawant, S.V., Singh, P.K. and Tuli, R. (2010) Rabies glycoprotein fused with B subunit of cholera toxin expressed in tobacco plants folds into biologically active pentameric protein. Protein Expr. Purif. 70, 184–190.

Ruhlman, T., Verma, D., Samson, N. and Daniell, H. (2010) The role of heterologous chloroplast sequence elements in transgene integration and expression. Plant Physiol. 152, 2088–2104.

Ruiz, V., Mozgovoj, M.V., Dus Santos, M.J. and Wigdorovitz, A. (2015) Plant-based oral veterinary vaccines: a potential way to combat the emerging multidrug-resistant Escherichia coli strain in piglets. Vaccine 33, 570–578.

Runciel, C., Westessou, D., Andino, R. and DeRisi, J.L. (2013) Identification and manipulation of the molecular determinants influencing poliovirus recombination. PLoS Pathog. 9, e1003164.

Rybicki, E.P. (2014) Plant-based vaccines against viruses. Virol. J. 11, 25456382.

Sack, M., Hofbauer, A., Fischer, R. and Stoger, E. (2015) The increasing value of plant-based medicines. Curr. Opin. Biotechnol. 23, 163–170.

Satish, K., Srimaran, R., Subramanian, B.M., Rao, N.H., Balaji, K., Narasu, M.L. and Srinivasan, V. (2011) Plant expressed EtMIC2 is an effective immunogen for protection against coccidiosis in chicken. Curr. Opin. Biotechnol. 22, 1071–1077.

Shahi, A.R. (2015) Cloning and expression of fusion (F) and fusion (G) glycoprotein of Chlamydia trachomatis in transgenic tobacco plants. J. Biotechnol. 170, doi: 10.1016/j.jbiotec.2014.10.001.

Shen, H., Qian, B., Chen, W., Liu, Z., Yang, L., Zhang, D. and Liang, W. (2010) Plant-expressed HA as a seasonal influenza vaccine antigen used as an oral vaccine protects against toxoplasmosis in mice. Vaccine 28, 9201–9208.

Shoji, Y., Chichester, J.A., Bi, H., Musiychuk, K., de la Rosa, P., Goldschmidt, L., Afsharifar, A.R. and Takeyama, N., Kiyono, H. and Yuki, Y. (2015) Plant-based vaccines for animals and humans: recent advances in technology and clinical trials. Therapeut. Adv. Vaccines, doi: 10.1177/2051013615613272.

Steel, D., Becken, S. and Davis, C. (2015) Impact of Norovirus in the cruise ship industry. Griffith Institute for Tourism Research Report, No 8 with ISSN 2023-4870 (Online).

Su, J., Zhu, L., Sherman, A., Wang, X., Lin, S., Kamesh, A., Norikane, J.H. et al. (2015) Low cost industrial production of coagulation factor IX bioencapsulated in lettuce cells for oral tolerance induction in hemophilia B. Biomaterials, 70, 84–93.

Takeyama, N., Kyono, H. and Yuki, Y. (2015) Plant-based vaccines for animals and humans: recent advances in technology and clinical trials. Therapeut. Adv. Vaccines, doi: 10.1177/2051013615613272.

Thrusfield, M. (2013) Veterinary Epidemiology. ISBN 0-7506-1496-X. Elsevier.

Takahara, D. (2013) Rice-based oral antibody fragment prophylaxis and therapy against rotavirus infection. J. Clin. Investig. 123, 3829.

Topp, E., Iwini, R., McAllister, T., Lessard, M., Joenius, J.J., Kolotkin, I., Conrad, U., et al. (2016) The case for plant-made veterinary immunotherapeutics. Biotechnol. Adv. 34, 597–604.

Tremblay, R., Wang, D., Jeuniar, A.M. and Ma, S. (2010) Tobacco, a highly efficient green bioreactor for production of therapeutic proteins. Biotechnol. Adv. 28, 214–221.

Uvarova, E.A., Belavin, P.A., Pernyakov, N.V., Zagorskaya, A.A., Nosareva, O.V., Kakimzanova, A.A. and Deineko, E.V. (2013) Oral immunogenicity of plant-made Mycobacterium tuberculosis ESAT6 and CFP10. BioMed Res. Int. 2013, Bgp, doi: 10.1155/2013/316304.

Wang, Y., Deng, H., Zhang, X., Xiao, H., Jiang, Y., Song, Y., Fang, L. et al. (2009) Generation and immunogenicity of Japanese encephalitis virus envelope protein expressed in transgenic rice. Biochem. Biophys. Res. Commun. 380, 292–297.

Wang, Y., Shen, Q., Jiang, Y., Song, Y., Fang, L., Xiao, S. and Chen, H. (2012) Immune response of foot-and-mouth disease virus structural polyprotein P1 expressed in transgenic rice. J. Virol. Methods, 181, 12–17.

Wolfson, W. (2013) Grow your own: protalix BioTherapeutics produces drugs in carrot cells. Chem. Biol. 20, 969–970.

Wu, J., Yu, L., Li, L., Hu, J., Zhou, J. and Zhou, X. (2007) Oral immunization with transgenic rice seeds expressing VP2 protein of infectious bursal disease virus induces protective immune responses in chickens. Plant Biotechnol. J. 5, 570–578.

Xiao, Y., Kwon, K.-C., Hoffman, B.E., Kamesh, A., Jones, N.T., Herzog, H.R. and Daniell, H. (2016) Low cost delivery of proteins bioencapsulated in plant cells to human non-immune or immune modulatory cells. Biomaterials, 80, 68–79.

Xiong, N., Zhang, Y., Wang, Y., Yang, B-Y. and Chen, S-Y. (2008) Isolation and identification of canine parvovirus serotype 2a and its VP2 protein expression in transgenic tobacco. Virologica Sinica, 23, 203–210.

Yalcino, M., Ferran, I., Becher, M.L., Sander, V., Sanchez, V.R., Martin, V., Veramendi, J. et al. (2012) A chloroplast-derived Toxoplasma gondii GRA4 antigen used as an oral vaccine protects against toxoplasmosis in mice. Plant Biotechnol. J. 10, 1136–1144.

Yusibov, V. and Rabindran, S. (2008) Recent progress in the development of plant derived vaccines. Expert Rev. Vaccines, 7, 1173–1183.

Yusibov, V., Stressenfield, S.J. and Kushner, N. (2011) Clinical development of plant-produced recombinant pharmaceuticals: vaccines, antibodies and beyond. Human Vaccines, 7, 313–321.

Zhang, X., Yuan, Z., Guo, X., Li, L., Li, Z. and Wang, Q. (2008) Expression of Chlamydia psittaci MOMP heat-labile toxin B subunit fusion gene in transgenic rice. Biotechnol. Adv., 26, 2930–2934.

Zhang, S.-Z., Zhang, G.-L., Rong, T.-Z., Li, P., Gong, Z. and Zhang, Y.-G. (2011) Transformation of two VP1 genes of O-and Asia 1-Type foot-and-mouth disease virus into maize. Agricul. Sci. China, 10, 661–667.

Zhang, Y., Chen, S., Li, J., Liu, Y., Hu, Y. and Cai, H. (2012) Oral immunogenicity of potato-derived antigens to Mycobacterium tuberculosis in mice. Acta Biochim. Biophys. Sin. doi: 10.1093/abbs/gms068.

Zhang, X.-X., Yu, H., Wang, X.-H., Li, X.-Z., Zhu, Y.-P., Li, H.-X., Luo, S.-J. et al. (2013) Protective efficacy against Chlamydia psittaci by oral immunization based on transgenic rice expressing MOMP in mice. Vaccine, 31, 698–703.

Zhou, J.-Y., Wu, J.-X., Cheng, L.-Q., Zheng, X.-J., Gong, H., Shang, S.-B. and Zhou, E.-M. (2003) Expression of immunogenic S1 glycoprotein of infectious bronchitis virus in transgenic potatoes. J. Virol., 77, 9090–9093.

Zhou, B., Zhang, Y., Wang, X., Dong, J., Wang, B., Han, C., Yu, J. et al. (2010) Oral administration of plant-based rotavirus VP6 induces antigen-specific IgAs, IgGs and passive protection in mice. Vaccine, 28, 6021–6027.